Treats venous thrombosis and its extension, pulmonary embolism (PE). ANDA 40416, held by Upsher Smith Labs. Warfarin Sodium.
As of Nov 15, 2026, ANDA 40416 (Jantoven), held by Upsher Smith Labs, was first approved by FDA on Oct 2, 2003, with 10 approved supplements and 0 published complete response letters.
JANTOVEN is indicated for: Prophylaxis and treatment of venous thrombosis and its extension, pulmonary embolism (PE). Prophylaxis and treatment of thromboembolic complications associated with atrial fibrillation (AF) and/or cardiac valve replacement. Reduction in the risk of death, recurrent myocardial infarction (MI), and thromboembolic events such as stroke or systemic embolization after myocardial infarction. Limitations of Use Warfarin Sodium has no direct effect on an established thrombus, nor does it reverse ischemic tissue damage.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Oct 2, 2003 | Original application | Approved | None posted |
| Jantoven1MG · tablet;oral | Warfarin Sodium | Rx |
| Jantoven2MG · tablet;oral | Warfarin Sodium | Rx |
| Jantoven2.5MG · tablet;oral | Warfarin Sodium | Rx |
| Jantoven3MG · tablet;oral | Warfarin Sodium | Rx |
| Jantoven4MG · tablet;oral | Warfarin Sodium | Rx |
| Jantoven5MG · tablet;oral | Warfarin Sodium | Rx |
| Jantoven6MG · tablet;oral | Warfarin Sodium | Rx |
| Jantoven7.5MG · tablet;oral | Warfarin Sodium | Rx |
| Jantoven10MG · tablet;oral | Warfarin Sodium | Rx |
| Sep 20, 2019 | Supplement 31Labeling · Standard review | Approved | None posted |
| Sep 20, 2019 | Supplement 33Labeling · Standard review | Approved | None posted |
| Jun 30, 2015 | Supplement 28Labeling · Standard review | Approved | None posted |
| Mar 27, 2012 | Supplement 26Labeling | Approved | None posted |
| May 20, 2010 | Supplement 22Labeling | Approved | None posted |
| Mar 28, 2008 | Supplement 16Labeling | Approved | None posted |
| Jul 11, 2007 | Supplement 14Labeling | Approved | None posted |
| Jan 12, 2007 | Supplement 11Labeling | Approved | None posted |
| May 5, 2006 | Supplement 6Labeling | Approved | None posted |
| Nov 29, 2004 | Supplement 5Labeling | Approved | None posted |
| Oct 2, 2003 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters